MedTrace Logo

Sugammadex: Effect on the Awareness Monitoring and Hemodynamics

NCT01301261 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-06-19

No results posted yet for this study

Summary

Sugammadex is used to reverse the neuromuscular blocking effect of steroid neuromuscular blockers. Its cardiovascular effects and effect on brain cortex, if any, may be associated to the reversal of the neuromuscular block. The aim of the study was to investigate the pure effects of sugammadex in the absence of the agonist.

Conditions

  • Surgical Procedure, Unspecified

Interventions

DRUG

sugammadex

Sugammadex 2 mg/kg when a two count of train of four appears

DRUG

Sugammadex 4 mg/kg

Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears

DRUG

Sugammadex 16mg/kg

Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-02-28

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301261 on ClinicalTrials.gov